TG Therapeutics Inc

TGTX

28.860USD

+1.100+3.96%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

TG Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

81 / 159

Overall Ranking

209 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

TG Therapeutics Inc Highlights

StrengthsRisks

TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 11713.43% year-on-year.

Fairly Valued

The company’s latest PE is 9.43, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 103.02M shares, decreasing 14.69% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 35.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of -0.19.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

44.167

Target Price

+51.67%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of TG Therapeutics Inc is 8.16, ranking 81 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 161.71M, representing a year-over-year increase of 92.79%, while its net profit experienced a year-over-year increase of 9974.61%.

Score

Industry at a Glance

Previous score

8.16

Change

0



Financials

6.02

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.99

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.78

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of TG Therapeutics Inc is 4.54, ranking 157 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 9.43, which is 2732.93% below the recent high of 267.17 and 3758.23% above the recent low of -345.00.

Score

Industry at a Glance

Previous score

4.54

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 81/159

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of TG Therapeutics Inc is 7.56, ranking 103 out of 159 in the Pharmaceuticals industry. The average price target is 49.00, with a high of 60.00 and a low of 13.00.

Score

Industry at a Glance

Previous score

7.56

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of TG Therapeutics Inc is 6.92, ranking 96 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 32.44 and the support level at 26.09, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.63

Change

0.29

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of TG Therapeutics Inc is 5.00, ranking 73 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 64.89%, representing a quarter-over-quarter increase of 1.53%. The largest institutional shareholder is The Vanguard, holding a total of 15.80M shares, representing 9.95% of shares outstanding, with 1.49% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

18.83M

-1.57%

The Vanguard Group, Inc.

Star Investors

15.49M

-1.83%

Weiss (Michael S)

9.16M

-33.77%

State Street Investment Management (US)

8.10M

+6.33%

ClearBridge Investments, LLC

4.64M

+52.15%

Soleus Capital Management, L.P.

3.84M

+71.34%

Geode Capital Management, L.L.C.

3.44M

-1.33%

Congress Asset Management Company, LLP

1.00M

--

Hood River Capital Management LLC

1.55M

-0.94%

Pictet Asset Management Ltd.

1.61M

-15.62%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of TG Therapeutics Inc is 7.15, ranking 43 out of 159 in the Pharmaceuticals industry. The company's beta value is 1.88. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. TG Therapeutics Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

TG Therapeutics Inc

TGTX

6.83 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mckesson Corp

MCK

9.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Gilead Sciences Inc

GILD

8.92 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

8.86 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Regeneron Pharmaceuticals Inc

REGN

8.72 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mirum Pharmaceuticals Inc

MIRM

8.70 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment